# EDGAR Filing Document

**Accession Number:** 0001653087
**File Stem:** 0001193125-25-140731
**Filing Date:** 2025-6
**Character Count:** 18273
**Document Hash:** 8b2f1ee46cd46f96d6f1eb02ca9e5f66
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-140731.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001193125-25-140731

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250609

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alector, Inc.
- **CENTRAL INDEX KEY:** 0001653087
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822933343
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38792
- **FILM NUMBER:** 251046510

**BUSINESS ADDRESS:**
- **STREET 1:** 131 OYSTER POINT BLVD., SUITE 600
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-231-5660

**MAIL ADDRESS:**
- **STREET 1:** 131 OYSTER POINT BLVD., SUITE 600
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alector LLC
- **DATE OF NAME CHANGE:** 20150915

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 9, 2025

## Alector, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38792** | **82-2933343** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |
| **131 Oyster Point Blvd.**<br> **Suite 600** | | |
| **South San Francisco, California** |  | **94080** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (415) 231-5660

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock | ALEC | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

On June 9, 2025, Dr. Marc Grasso gave notice of his decision to resign from his position as Chief Financial Officer of Alector, Inc. ("Alector") in order to pursue other opportunities. His resignation will be effective on June 20, 2025. Dr. Grasso has served as Alector's Chief Financial Officer since February 2022, and Alector extends its gratitude to Dr. Grasso for his years of service and contributions to Alector.

Effective upon Dr. Grasso's resignation, Neil Berkley will be Chief Business Officer and Interim Chief Financial Officer, serving as the principal financial officer of Alector, and Grace Wong-Sarad will be the Vice President, Accounting, serving as the principal accounting officer of Alector.

Mr. Berkley, age 51, first joined Alector as Chief Business Officer in March of 2024. Mr. Berkley brings over two decades of experience in corporate development and business development across pharma and biotech. Before joining Alector, from November 2022 to March 2024, Mr. Berkley was Chief Corporate Development Officer at Juvena Therapeutics Inc., a private biotech company focused on metabolic and muscle diseases. From July 2021 to July 2022, Mr. Berkley was Chief Business Officer at AbCellera Biologics, Inc., a public biotech company focused on discovering novel antibody therapeutics, and from April 2019 to July 2021, Mr. Berkley held roles of increasing responsibility, including Vice President and Head of Business Development, at Halozyme Therapeutics, Inc., a public biotech company focused on enabling drug delivery platforms. Earlier in his career, Mr. Berkley held various roles at Acadia Pharmaceuticals Inc., GSK, Cadence Pharmaceuticals Inc., and Mpex Pharmaceuticals Inc. Mr. Berkley holds a B.S. in Molecular Biology from UC San Diego, as well as an M.S. in Cellular and Molecular Biology and an MBA from San Diego State University.

Mr. Berkley's annual compensation consists of a base salary of $455,000, and he is eligible to receive a performance bonus equal to 40% of his annual base salary. In connection with his appointment as the principal financial officer, Mr. Berkley will be eligible to receive a retention bonus in the amount of $91,000 payable in December 2025. Mr. Berkley is also entitled to receive other employee benefits generally available to all employees of Alector.

Ms. Wong-Sarad, age 51, first joined Alector in August of 2019 as Senior Director, Controller and was promoted to Vice President, Accounting in June of 2022. Prior to joining Alector, Ms. Wong-Sarad served as Corporate Controller at Achaogen, Inc., Vice President, Controller at Symic Bio, Senior Director, Corporate Controller at Hyperion Therapeutics, Inc., various positions including Senior Audit Manager at KPMG, LLP in both the United States and Thailand, and various positions including Associate Manager at Arthur Andersen LLP in Manila, Philippines (now Ernst & Young Philippines). Ms. Wong-Sarad holds a B.S. in Accountancy from San Pedro College of Business Administration in the Philippines.

Ms. Wong-Sarad's annual compensation consists of a base salary of $343,636, which will increase to $363,636 as of June 30, 2025, and she is eligible to receive a performance bonus equal to 30% of her annual base salary. In connection with her appointment as principal accounting officer, Ms. Wong-Sarad will be eligible to receive a retention bonus in the amount of $54,545 payable in December 2025. Ms. Wong-Sarad is also entitled to receive other employee benefits generally available to all employees of Alector.

Mr. Berkley and Ms. Wong-Sarad each have previously entered into a change in control and severance agreement (with Tier 2 and Tier 3 benefits, respectively) and will enter into a standard form of indemnification agreement with Alector, each in the form as filed with the Securities and Exchange Commission on January 7, 2019 as Exhibits 10.12 and 10.1 to Registration Statement on Form S-1, respectively, each of which is incorporated herein by reference.

Neither Mr. Berkley nor Ms. Wong-Sarad has any family relationships that require disclosure pursuant to Item 401(d) of Regulation S-K or has been involved in any transactions that require disclosure pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. Berkley or Ms. Wong-Sarad and any other person pursuant to which either of them was appointed to their respective positions with Alector.

On June 13, 2025, Alector issued a press release announcing the appointment of Mr. Berkley as its Interim Chief Financial Officer. The press release is attached hereto as Exhibit 99.1. The information included in the press release in Exhibit 99.1 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended.

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.**  |

---

On June 11, 2025, Alector held its 2025 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, Alector's stockholders voted on three proposals, each of which is described in more detail in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2025. The following is a brief description of each matter voted on and the certified results, including the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter.

------

1. The Class I director nominees were elected to serve until Alector's 2028 annual meeting of stockholders and until their successors are elected and qualified. The voting results were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Director Name** | **Votes For** | **Votes For** | **Votes Withheld** | **Votes Withheld** | **Broker Non-Vote** | **Broker Non-Vote** |
|  Arnon Rosenthal, Ph.D. |  | 69140255 |  | 876180 |  | 19513598 |
|  Paula Hammond, Ph.D. |  | 62643296 |  | 7373139 |  | 19513598 |

---

2. Stockholders ratified the appointment of Ernst & Young LLP as Alector's independent registered accounting firm for the fiscal year ending December 31, 2025. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Vote** |
| 88933030 | 84974 | 512029 | 0 |

---

3. Stockholders approved, on a non-binding advisory basis, the compensation of Alector's named executive officers as disclosed in the proxy statement for the Annual Meeting, known as the Say-on-Pay vote. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Vote** |
| 68738538 | 1141227 | 136670 | 19513598 |

---

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit<br>No. | Description |
| 99.1 | [Press Release, dated June 13, 2025](d58708dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **ALECTOR, INC.** |
| Date: June 13, 2025 | By: | /s/ Arnon Rosenthal |
|  |  | Arnon Rosenthal, Ph.D.<br> Co-founder and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

---

| | |
|:---|:---|
| ![LOGO](g58708g0613210051491.jpg) | NEWS RELEASE |

---

**Alector Provides Executive Leadership Update** 

*— Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D.,* 

*effective June 20, 2025—* 

**South San Francisco, Calif.,** June 13, 2025 — Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer (CFO), Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M.B.A., the company's Chief Business Officer, will assume the role of Interim CFO while continuing in his current position.

"Marc has been a valuable member of our leadership team and a strong steward of the company since joining Alector in February 2022," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "He played a key role in strengthening our financial position and building a high-performing finance team. With cash runway into the second half of 2027, Alector is well positioned to advance our clinical, preclinical, and research programs through key inflection points. As Neil steps into the role of Interim CFO, the solid financial infrastructure established under Marc's leadership, combined with Neil's experience in corporate development and business strategy, will help ensure a smooth transition. We thank Marc for his significant contributions and wish him continued success in his next chapter, and we look forward to Neil's expanding leadership role as Chief Business Officer and Interim CFO."

Alector currently has two late-stage clinical candidates being developed in collaboration with GSK. The company remains on track to report topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a *GRN* gene mutation (FTD-*GRN*) in Q4 2025 and has completed enrollment in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease (AD) in April 2025. Additionally, Alector continues to strategically pursue research and preclinical programs selectively supported by its proprietary blood-brain barrier technology platform, Alector Brain Carrier (ABC), including ADP037-ABC, its brain-penetrant anti-amyloid beta antibody for AD, and ADP050-ABC, its brain-penetrant GCase enzyme replacement therapy for Parkinson's disease.

"It has been an honor to contribute to Alector's mission of developing innovative therapies for neurodegenerative diseases," said Dr. Grasso. "I'm proud of the financial position the team has established to support the company's progress. I have full confidence in Neil and the entire leadership team to guide Alector through this next phase. I remain committed to ensuring a smooth transition and wish Alector continued success in advancing its important pipeline."

------

Alector Provides Executive Leadership Update

**About Neil Berkley, M.B.A.** 

Neil Berkley joined Alector in March 2024 as Chief Business Officer, bringing more than two decades of experience in corporate and business development across pharma and biotech. Before joining Alector, he served as Chief Corporate Development Officer at Juvena Therapeutics, Chief Business Officer at AbCellera, and Vice President and Head of Business Development at Halozyme Therapeutics. Earlier in his career, he held leadership roles at Cadence Pharmaceuticals, Acadia, and GSK, among others. He holds a B.S. in Molecular Biology from the University of California, San Diego, as well as an M.S. in Cellular and Molecular Biology and an M.B.A. from San Diego State University.

**About Alector** 

Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit <u>www.alector.com.</u>

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, blood-brain barrier technology platform, research and preclinical pipeline, planned and ongoing preclinical studies and clinical trials, anticipated timing of and detail regarding release of data for INFRONT-3, expected milestones, expectations of our collaboration with GSK, expectations of our interactions with regulatory authorities, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Quarterly Report on Form 10-Q filed on May 8, 2025, with the Securities and Exchange Commission ("SEC"), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.

**Alector Contacts**:

Alector

Katie Hogan

202-549-0557

<u>katie.hogan@alector.com</u> 

------

Alector Provides Executive Leadership Update

Argot Partners (media)

David Rosen

646-461-6387

<u>alector@argotpartners.com</u>

Argot Partners (investors)

Laura Perry

212-600-1902

<u>alector@argotpartners.com</u>